The companies said that the partnership will combine Nucleai's expertise in extracting and analyzing the quantitative spatial features of pathology images and Adlai Nortye's expertise in drug development and immunotherapy to glean insights into the tumor microenvironment and translate these findings into actionable biomarkers for use in clinical trials.

The initial focus of the partnership will be to identify patients with metastatic squamous cell carcinoma of the head and neck who may benefit from treatment with buparlisib; the collaboration will expand to other clinical trials and indications in the future, the firms added.

Biomarker predicts response to chemo-immunotherapy in lung cancer patients
Researchers have found a biomarker that provides an early indication of whether a patient is responding to chemo-immunotherapy.

Bladder cancer biomarker signature could identify likely responders to checkpoint inhibitors
Scientists have found signatures associated with the response of bladder cancer to immune checkpoint inhibitors, suggesting that it may be possible to...

Ultivue enters several partnerships for AI-powered phenomics solutions
Ultivue has entered into multiple partnerships to expand on the use of artificial intelligence (AI) to provide high quality analysis of clinical trial...

Nucleai closes $33M series B financing
Artificial intelligence-powered spatial biology company Nucleai closed a $33 million series B financing round, which it will use to advance its spatial...

Nucleai and Debiopharm team up for cancer drug development
Biomarker discovery company Nucleai will work with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per...